Form 4: Roivant Sciences CAO Receives Equity Compensation

Chief Accounting Officer Jennifer Humes was granted restricted stock units and stock options as part of a compensation package.

Summary

• Jennifer Humes, Chief Accounting Officer of Roivant Sciences, received an equity grant on April 20, 2026.
• The grant includes 29,173 restricted stock units (RSUs) and 27,157 stock options.
• The stock options have an exercise price of $29.08 per share.
• The RSUs vest over a four-year period, starting with 25% on the first anniversary and the remainder in quarterly installments.
• The stock options vest over a four-year period, starting with 25% on the first anniversary and the remainder in monthly installments.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral for the company's operational outlook.

Positives

• Equity-based compensation aligns the interests of the Chief Accounting Officer with those of shareholders.
• The multi-year vesting schedule encourages long-term retention of key executive talent.

Negatives

• The issuance of new equity results in minor dilution to existing shareholders.

Risks

• Future share price volatility could impact the ultimate value realized by the executive from these grants.
• Retention risk remains if the executive does not complete the multi-year service requirements for full vesting.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on executive compensation structure.

Management Comments

• The grants are subject to the reporting person's continuous service through each applicable vesting date.

Industry Context

StockSavvy.ai notes that equity-based compensation for C-suite executives is standard practice in the biotechnology sector to incentivize long-term performance and align management with shareholder outcomes.

Comparison to Industry Standards

• The four-year vesting schedule is consistent with standard corporate governance practices for executive equity awards in the U.S. biotech industry.
• The use of both RSUs and stock options is a common compensation mix for high-growth pharmaceutical companies.

Corporate Governance

Stakeholder Impact

• Shareholders experience minor dilution from the issuance of new equity.

Next Steps

• Vesting of 25% of RSUs and options on April 20, 2027, subject to continued employment.

Key Dates

Keywords

Roivant Sciences, ROIV, Form 4, Insider Trading, Equity Compensation, Chief Accounting Officer